产品详情
简单介绍：
重组人白细胞介素-36受体拮抗剂蛋白蛋白与其它公司提供的重组蛋白不同，rHuIL-36RA蛋白产品为采用CFS的无细胞麦胚蛋白合成系统表达出来的重组蛋白，可表达出对细胞有毒性、易被蛋白酶降解的蛋白；并获得具有良好的可溶性，并有翻译后修饰、从而部分具有功能的蛋白.同时独有的全自动蛋白纯化技术则简便高效，将蛋白纯化过程中对蛋白的损伤降低到*小程度.重组人白细胞介素-36受体拮抗剂蛋白蛋白（全长序列）产品可用于Western Blot验证、抗体制备、蛋白检测、ELISA等试验中.
详情介绍：
重组人白细胞介素-36受体拮抗剂蛋白蛋白
| Synonyms | IL-1RP3, IL-1HY1, IL-1 delta, IL-1F5, IL-1ra homolog 1, IL-1L1 |
| Species | Human |
| Accession | Q9UBH0 |
| GeneID | 26525 |
| Source | Escherichia coli. |
| Molecular Weight | 重组人白细胞介素-36受体拮抗剂蛋白蛋白Approximately 16.8 kDa, a single non-glycosylated polypeptide chain containing 154 amino acids. |
| Quantity | 5µg/25µg/1000µg |
| AA Sequence | VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD |
| Purity | 重组人白细胞介素-36受体拮抗剂蛋白蛋白> 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | 重组人白细胞介素-36受体拮抗剂蛋白蛋白Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/µg of rHuIL-36RA as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重组人白细胞介素-36受体拮抗剂蛋白蛋白 | |
| SDS-PAGE |  |
| Reference | 1. Born TL, Smith DE, Garka KE, et al. 2000. J Biol Chem. 275:41528. 2. Dunn EF, Gay NJ, Bristow AF, et al. 2003. Biochemistry. 42:10938-44. 3. Barton JL, Herbst R, Bosisio D, et al. 2000. Eur J Immunol. 30:3299-308. 4. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6. 5. Towne JE, Renshaw BR, Douangpanya J, et al. 2011. J Biol Chem. 286:42594-602. |
| Background | Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36α (IL-1F6), IL-36β (IL-1F8), and IL-36γ (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, The receptor for IL-36RA has not been positively identified. Indirect evidence suggests it is IL-1Rrp2. Recombinant human IL-36 RA contains 154 amino acid residues and it shares 91 % a.a. sequence identity with murine IL-36RA. |
